• Product name
  • Description
    Rabbit polyclonal to JAK3
  • Host species
  • Tested applications
    Suitable for: WB, IPmore details
  • Species reactivity
    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide:


    , corresponding to amino acids 785 - 799 of Mouse JAK3

  • Positive control
    • HeLa cell lysate, Jurkat cell lysate and HepG2 cell lysate



Our Abpromise guarantee covers the use of ab78116 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500. Predicted molecular weight: 125 kDa.
IP Use at an assay dependent dilution.


  • Function
    Tyrosine kinase of the non-receptor type, involved in the interleukin-2 and interleukin-4 signaling pathway. Phosphorylates STAT6, IRS1, IRS2 and PI3K.
  • Tissue specificity
    In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins.
  • Involvement in disease
    Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:600802]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
  • Sequence similarities
    Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
    Contains 1 FERM domain.
    Contains 1 protein kinase domain.
    Contains 1 SH2 domain.
  • Domain
    Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.
  • Post-translational
    Tyrosine phosphorylated in response to IL-2 and IL-4.
  • Cellular localization
    Endomembrane system. Wholly intracellular, possibly membrane associated.
  • Information by UniProt
  • Database links
  • Alternative names
    • EC antibody
    • JAK 3 antibody
    • JAK L antibody
    • JAK-3 antibody
    • Jak3 antibody
    • JAK3 HUMAN antibody
    • JAK3_HUMAN antibody
    • JAKL antibody
    • Janus kinase 3 (a protein tyrosine kinase, leukocyte) antibody
    • Janus kinase 3 antibody
    • Janus Kinase3 antibody
    • L JAK antibody
    • L-JAK antibody
    • Leukocyte janus kinase antibody
    • LJAK antibody
    • Protein tyrosine kinase leukocyte antibody
    • Tyrosine protein kinase JAK3 antibody
    • Tyrosine-protein kinase JAK3 antibody
    see all


  • Anti-JAK3 antibody (ab78116) at 1/500 dilution + HeLa cell lysate

    donkey anti-rabbit HRP conjugated IgG at 1/1000 dilution

    Predicted band size: 125 kDa
    Observed band size: 125 kDa

  • All lanes : Anti-JAK3 antibody (ab78116) at 1/500 dilution

    Lane 1 : Jurkat cell lysate
    Lane 2 : HepG2 cell lysate
    Lane 3 : HeLa cell lysate

    All lanes : donkey anti-rabbit HRP conjugated IgG at 1/1000 dilution

    Predicted band size: 125 kDa
    Observed band size: 125 kDa


ab78116 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

I am sorry to hear that the antibody still giving you wrong band size. The antibody should have given ˜120 kDa band however we are unsure about the cause of the problem. In order to proceed further, I am happy to provide the replacement which I agreed ...

Read More

Thank you very much or confirming details.

I have read the protocol you have used which seems absolutely fine to me. However as we do not have received any other complaints so I would like to suggest following troubleshooting tips which might ...

Read More

Thank you for your email. I am sorry to hear that you have been experiencing problems with this antibody.

I have read the details you have kindly provided and would like to investigate this antibody further. Could you provide the protocol deta...

Read More


Sign up